Literature DB >> 23972394

Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.

Haibo Wang1, George W Smith, Zhihong Yang, Yanchao Jiang, Manabu McCloskey, Kenneth Greenberg, Pete Geisen, William D Culp, John Flannery, Tal Kafri, Scott Hammond, M Elizabeth Hartnett.   

Abstract

Vascular endothelial growth factor (VEGF) A is implicated in aberrant angiogenesis and intravitreous neovascularization (IVNV) in retinopathy of prematurity (ROP). However, VEGFA also regulates retinal vascular development and functions as a retinal neural survival factor. By using a relevant ROP model, the 50/10 oxygen-induced retinopathy (OIR) model, we previously found that broad inhibition of VEGFA bioactivity using a neutralizing antibody to rat VEGF significantly reduced IVNV area compared with control IgG but also significantly reduced body weight gain in the pups, suggesting an adverse effect. Therefore, we propose that knockdown of up-regulated VEGFA in cells that overexpress it under pathological conditions would reduce IVNV without affecting physiological retinal vascular development or overall pup growth. Herein, we determined first that the VEGFA mRNA signal was located within the inner nuclear layer corresponding to CRALBP-labeled Müller cells of pups in the 50/10 OIR model. We then developed a lentiviral-delivered miR-30eembedded shRNA against VEGFA that targeted Müller cells. Reduction of VEGFA by lentivector VEGFA-shRNAetargeting Müller cells efficiently reduced 50/10 OIR up-regulated VEGFA and IVNV in the model, without adversely affecting physiological retinal vascular development or pup weight gain. Knockdown of VEGFA in rat Müller cells by lentivector VEGFA-shRNA significantly reduced VEGFR2 phosphorylation in retinal vascular endothelial cells. Our results suggest that targeted knockdown of overexpressed VEGFA in Müller cells safely reduces IVNV in a relevant ROP model.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23972394      PMCID: PMC3763762          DOI: 10.1016/j.ajpath.2013.05.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity.

Authors:  Karel Allegaert; Christine Vanhole; Ingele Casteels; Gunnar Naulaers; Anne Debeer; Veerle Cossey; Hugo Devlieger
Journal:  J AAPOS       Date:  2003-02       Impact factor: 1.220

2.  VEGF polymorphisms are associated with neovascular age-related macular degeneration.

Authors:  Amanda J Churchill; James G Carter; Helen C Lovell; Conor Ramsden; Steven J Turner; Anna Yeung; Julia Escardo; Denize Atan
Journal:  Hum Mol Genet       Date:  2006-08-29       Impact factor: 6.150

3.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Authors:  Frank Stegmeier; Guang Hu; Richard J Rickles; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

4.  VEGF expression and receptor activation in the choroid during development and in the adult.

Authors:  Magali Saint-Geniez; Angel E Maldonado; Patricia A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

5.  Tissue oxygen levels control astrocyte movement and differentiation in developing retina.

Authors:  Y Zhang; R M Porat; T Alon; E Keshet; J Stone
Journal:  Brain Res Dev Brain Res       Date:  1999-12-10

6.  Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration.

Authors:  Imran A Bhutto; D Scott McLeod; Takuya Hasegawa; Sahng Y Kim; Carol Merges; Patrick Tong; Gerard A Lutty
Journal:  Exp Eye Res       Date:  2005-07-12       Impact factor: 3.467

7.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

8.  Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats.

Authors:  K Abdulmalek; F Ashur; N Ezer; F Ye; S Magder; S N Hussain
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-09       Impact factor: 5.464

9.  Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors.

Authors:  Kenneth P Greenberg; Scott F Geller; David V Schaffer; John G Flannery
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

10.  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity.

Authors:  A Hellstrom; C Perruzzi; M Ju; E Engstrom; A L Hard; J L Liu; K Albertsson-Wikland; B Carlsson; A Niklasson; L Sjodell; D LeRoith; D R Senger; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

View more
  25 in total

1.  VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.

Authors:  Zhihong Yang; Haibo Wang; Yanchao Jiang; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2014-03-12       Impact factor: 4.307

Review 2.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 3.  Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Clin Perinatol       Date:  2014-09-23       Impact factor: 3.430

Review 4.  Pathophysiology and mechanisms of severe retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Ophthalmology       Date:  2014-10-14       Impact factor: 12.079

Review 5.  The Effects of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Erythropoietin, and Their Interactions in Angiogenesis: Implications in Retinopathy of Prematurity.

Authors:  Thaonhi Cung; Haibo Wang; M Elizabeth Hartnett
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

6.  Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.

Authors:  Haibo Wang; Zhihong Yang; Yanchao Jiang; John Flannery; Scott Hammond; Tal Kafri; Sai Karthik Vemuri; Bryan Jones; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-04       Impact factor: 4.799

7.  Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.

Authors:  Yanchao Jiang; Haibo Wang; David Culp; Zhihong Yang; Lori Fotheringham; John Flannery; Scott Hammond; Tal Kafri; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

8.  LncRNA CCAT2 promotes angiogenesis in glioma through activation of VEGFA signalling by sponging miR-424.

Authors:  Sheng-Li Sun; Yu-Gao Shu; Mei-Yi Tao
Journal:  Mol Cell Biochem       Date:  2020-04-01       Impact factor: 3.396

9.  Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal Neovascularization.

Authors:  Haibo Wang; Xiaokun Han; Deeksha Gambhir; Silke Becker; Eric Kunz; Angelina Jingtong Liu; M Elizabeth Hartnett
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 10.  Emerging role of microRNAs in lipid metabolism.

Authors:  Zhihong Yang; Tyler Cappello; Li Wang
Journal:  Acta Pharm Sin B       Date:  2015-02-24       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.